Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271082 | 0.89 | MEN1 (0.63) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL12579133 | 0.88 | LMNA (0.55) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL12489711 | 0.88 | LMNA (0.55) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL2659482 | 0.87 | KMT2A (0.73) | KMT2AMEN1MRGPRX4NR4A2MAOB | |
| SCHEMBL391547 | 0.87 | MEN1 (0.71) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL1270779 | 0.86 | HPGD (0.53) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL2655968 | 0.85 | GCK (0.67) | KMT2AMEN1 | |
| SCHEMBL2656511 | 0.85 | HPGD (0.52) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL183994 | 0.84 | LMNA (0.70) | LMNAHPGDKMT2AMEN1MRGPRX4 | |
| SCHEMBL1271181 | 0.84 | LMNA (0.51) | LMNAHPGDKMT2AMEN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| EP-1697324-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054200-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | GCK, GALK1, PDXK | LMNA 898/4885HPGD 1892/4885KMT2A 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.